Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cerus Corp (CERS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 231,741
  • Shares Outstanding, K 104,860
  • Annual Sales, $ 39,280 K
  • Annual Income, $ -62,910 K
  • 36-Month Beta 1.83
  • Price/Sales 6.03
  • Price/Cash Flow 0.00
  • Price/Book 5.64

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.10 +5.24%
on 07/20/17
2.59 -14.67%
on 06/26/17
-0.21 (-8.68%)
since 06/20/17
3-Month
1.93 +14.51%
on 05/26/17
4.70 -52.98%
on 04/26/17
-2.02 (-47.75%)
since 04/20/17
52-Week
1.93 +14.51%
on 05/26/17
7.64 -71.07%
on 08/01/16
-4.37 (-66.41%)
since 07/20/16

Most Recent Stories

More News
INTERCEPT Blood System Highlighted at the International Society of Blood Transfusion (ISBT)

Cerus Corporation (NASDAQ:CERS) announced results of 16 abstracts presenting experiences with the INTERCEPT Blood System for platelets, plasma, and red blood cells during the 27th Regional...

CERS : 2.21 (unch)
Today's Research Reports on Stocks to Watch: Calithera Biosciences and Cerus Corporation

NEW YORK, NY / ACCESSWIRE / June 8, 2017 / Calithera Biosciences scored a big win on Wednesday after the FDA granted it Fast Track Designation on its cancer treatment CB-839. Cerus Corporation's shares...

CALA : 15.85 (-2.76%)
CERS : 2.21 (unch)
Cerus Falls 25.33% on Heavy Volume: Watch For Potential Rebound

Cerus (NASDAQ:CERS) traded in a range yesterday that spanned from a low of $2.24 to a high of $2.83. Yesterday, the shares fell 25.3%, which took the trading range below the 3-day low of $2.95 on volume...

CERS : 2.21 (unch)
First Patient Transfused in Cerus' Phase III RedeS Study Evaluating Safety and Efficacy of the INTERCEPT Red Blood Cell System

Cerus Corporation (NASDAQ: CERS) announced today that the first patient has been transfused in Puerto Rico for the "INTERCEPT Blood System for Red Blood Cells in Regions at Potential Risk...

CERS : 2.21 (unch)
Investor Network: Cerus Corporation to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 3, 2017 / Cerus Corporation (NASDAQ: CERS) will be discussing their earnings results in their Q1 Earnings Call to be held May 3, 2017 at 4:15 PM Eastern Time.

CERS : 2.21 (unch)
Cerus to Release First Quarter 2017 Results on May 3, 2017

Cerus Corporation (NASDAQ:CERS) announced today that its first quarter results will be released on Wednesday, May 3, 2017, after the close of the stock market. The company will host a conference...

CERS : 2.21 (unch)
Cerus Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Cerus Corporation (NASDAQ:CERS) announced today that, on April 3, 2017, the compensation committee of the company's board of directors granted 21 new non-executive employees options to purchase...

CERS : 2.21 (unch)
Cerus Corporation Reports Fourth Quarter and Year End 2016 Results

Cerus Corporation (NASDAQ:CERS) today announced financial results for the fourth quarter and year ended December 31, 2016.

CERS : 2.21 (unch)
Cerus to Release Fourth Quarter and Year End 2016 Results on March 7, 2017

Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter and year end results for 2016 will be released on Tuesday, March 7, 2017, after the close of the stock market. The...

CERS : 2.21 (unch)
Research Reports Initiation on Biotech Stocks -- Portola Pharma, Tesaro, Sangamo Therapeutics, and Cerus

This morning, Stock-Callers.com puts focus on select equities to see how they have fared over the last few trading sessions: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Tesaro Inc. (NASDAQ: TSRO), Sangamo...

SGMO : 9.55 (+1.60%)
TSRO : 129.02 (+4.03%)
PTLA : 65.29 (+0.48%)
CERS : 2.21 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company...

See More

Support & Resistance

2nd Resistance Point 2.30
1st Resistance Point 2.25
Last Price 2.21
1st Support Level 2.13
2nd Support Level 2.06

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.